Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials

Authors

David Gruben (ORCID: https://orcid.org/0000-0003-3516-5289)
C. Kinch (ORCID: https://orcid.org/0000-0002-2712-1668)
A. Sellas (ORCID: https://orcid.org/0000-0003-2812-2467)
Gustavo Citera (ORCID: https://orcid.org/0000-0002-3724-1874)
Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
M. Valderrama (ORCID: https://orcid.org/0009-0009-7863-5456)
Susana Gómez (ORCID: https://orcid.org/0009-0003-2763-9146)

Institutions

Hebron University (PS)
Inserm (FR)
Pfizer (United States) (US)
Sorbonne Université (FR)
Assistance Publique – Hôpitaux de Paris (FR)
Instituto Nacional de Rehabilitación Psicofísica (AR)
Pitié-Salpêtrière Hospital (FR)
Vall d'Hebron Hospital Universitari (ES)
Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
Pfizer (Spain) (ES)
Pfizer (Canada) (CA)

Publication Details

Journal: Rheumatology and Therapy
Published: 2025-10-28
DOI: https://doi.org/10.1007/s40744-025-00800-7
Primary Topic: Spondyloarthritis Studies and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Pfizer

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials

David Gruben, C. Kinch, A. Sellas, Gustavo Citera et al.

Oct 28, 2025

Rheumatology and Therapy

Spondyloarthritis Studies and Treatments

article

Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials

David Gruben, C. Kinch, A. Sellas, Gustavo Citera, Laure Gossec, M. Valderrama, Susana Gómez

October 28, 2025article en

Abstract

No abstract available for this paper.

Rheumatology and TherapyVol. 12(6)

Hebron University (PS), Inserm (FR), Pfizer (United States) (US), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), Instituto Nacional de Rehabilitación Psicofísica (AR), Pitié-Salpêtrière Hospital (FR), Vall d'Hebron Hospital Universitari (ES), Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR), Pfizer (Spain) (ES), Pfizer (Canada) (CA)

Pfizer

Openalex Percentile: Top 55%

Spondyloarthritis Studies and Treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials — David Gruben, C. Kinch, et al. · Rheumatology and Therapy (2025) | TGRS Research Map | TGRS